open access

Vol 86, No 6 (2015)
ARTICLES
Get Citation

Colposcopic-histologic eligibility criteria for fertility-sparing surgical management in early-stage cervical cancer

Paweł Basta, Artur Ludwin, Łukasz Laskowicz, Krzysztof Okoń, Janina Schwartz
DOI: 10.17772/gp/2396
·
Ginekol Pol 2015;86(6).

open access

Vol 86, No 6 (2015)
ARTICLES

Abstract

Background: The decision whether fertility-sparing surgical management may be successfully applied in women with cervical cancer who wish to preserve their fertility remains a great therapeutic challenge. Such management is possible if no node metastases are expected and the risk of cancer spread beyond the cervix is limited. Thus, precise evaluation of tumor size is necessary. Objectives: The aim of the study was to establish cytologic, colposcopic and histologic eligibility criteria for fertilitysparing treatment in women with early-stage cervical cancer. Material and methods: The study included 119 women (aged 25-43 years) diagnosed and operated on due to malignant changes within the cervix. Each subject underwent cytologic and colposcopic examination, followed by histologic evaluation of a large, target section from the most suspicious area of the lesion. Results: Histologic evaluation revealed stage IA1 in 60 (50.4%), IA2 in 53 (44.5%), and IB1 in 6 (5.1%) patients. Histologic compatibility between target sections and evaluation of the surgical material was 59 (98.4%), 51 (96.2%), and (100%) for stages IA1, IA2, and IB1, respectively. Conclusions: Proper colposcopic assessment of early-stage invasive cervical cancer (IA) allows to identify the most adequate area for large wedge biopsy. That in turn makes it possible to establish proper histologic pre-treatment diagnosis, with an over 95% compatibility with the final histologic evaluation, what conditions fertility-sparing surgical treatment.

Abstract

Background: The decision whether fertility-sparing surgical management may be successfully applied in women with cervical cancer who wish to preserve their fertility remains a great therapeutic challenge. Such management is possible if no node metastases are expected and the risk of cancer spread beyond the cervix is limited. Thus, precise evaluation of tumor size is necessary. Objectives: The aim of the study was to establish cytologic, colposcopic and histologic eligibility criteria for fertilitysparing treatment in women with early-stage cervical cancer. Material and methods: The study included 119 women (aged 25-43 years) diagnosed and operated on due to malignant changes within the cervix. Each subject underwent cytologic and colposcopic examination, followed by histologic evaluation of a large, target section from the most suspicious area of the lesion. Results: Histologic evaluation revealed stage IA1 in 60 (50.4%), IA2 in 53 (44.5%), and IB1 in 6 (5.1%) patients. Histologic compatibility between target sections and evaluation of the surgical material was 59 (98.4%), 51 (96.2%), and (100%) for stages IA1, IA2, and IB1, respectively. Conclusions: Proper colposcopic assessment of early-stage invasive cervical cancer (IA) allows to identify the most adequate area for large wedge biopsy. That in turn makes it possible to establish proper histologic pre-treatment diagnosis, with an over 95% compatibility with the final histologic evaluation, what conditions fertility-sparing surgical treatment.
Get Citation

Keywords

cervical cancer / colposcopy / target biopsy / fertility sparing /

About this article
Title

Colposcopic-histologic eligibility criteria for fertility-sparing surgical management in early-stage cervical cancer

Journal

Ginekologia Polska

Issue

Vol 86, No 6 (2015)

DOI

10.17772/gp/2396

Bibliographic record

Ginekol Pol 2015;86(6).

Keywords

cervical cancer / colposcopy / target biopsy / fertility sparing /

Authors

Paweł Basta
Artur Ludwin
Łukasz Laskowicz
Krzysztof Okoń
Janina Schwartz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl